
Cyclin-dependent kinase 2 - Wikipedia
Cyclin-dependent kinase 2, also known as cell division protein kinase 2, or Cdk2, is an enzyme that in humans is encoded by the CDK2 gene. [5] [6] The protein encoded by this gene is a …
Cyclin Dependent Kinase 2 (CDK2) Inhibitors in Oncology …
Cyclin dependent kinase 2 (CDK2) is responsible for enforcing progression through the G1-S phase transition. Mutations and alterations in the CDK2 signaling pathway are associated with …
Cyclin-dependent kinase - Wikipedia
Cyclin-dependent kinases (CDKs) are a predominant group of serine/threonine protein kinases involved in the regulation of the cell cycle and its progression, ensuring the integrity and …
CDK2 Gene - GeneCards | CDK2 Protein | CDK2 Antibody
Mar 30, 2025 · CDK2 (Cyclin Dependent Kinase 2) is a Protein Coding gene. Diseases associated with CDK2 include Breast Cancer and Endometrial Hyperplasia. Among its related pathways …
Cyclin-Dependent Kinases (CDK) and Their Role in Diseases …
In dividing cells, cyclin-dependent kinase 2 (CDK2) is a major cell cycle component that controls the G1/S and S/G2 transitions.
Targeting CDK2 in cancer: challenges and opportunities for therapy
CDK2 and its regulatory subunits are deregulated in many human cancers and there is emerging evidence suggesting CDK2 inhibition elicits antitumor activity in a subset of tumors with …
Inhibition of the CDK2 and Cyclin A complex leads to autophagic ...
May 20, 2022 · Cyclin-dependent kinase 2 (CDK2) complex is significantly over-activated in many cancers. While it makes CDK2 an attractive target for cancer therapy, most inhibitors against …
Cyclin E/CDK2: DNA Replication, Replication Stress and Genomic ...
Transition through cell cycle phases is regulated by a family of Cyclin-Dependent Kinases (CDKs) in association with respective cyclin regulatory subunits. In normal cell cycles, E-type cyclins …
CDK2 heterobifunctional degraders co-degrade CDK2 and cyclin E …
Apr 17, 2025 · CCNE1 amplification drives aberrant CDK2-cyclin E1 activity in cancer. Despite activity of CDK2 inhibitors, their therapeutic margins are limited by poor CDK selectivity. We …
Discrete vulnerability to pharmacological CDK2 inhibition is …
Feb 9, 2025 · Here, the authors investigate CDK2-dependancy and response to CDK2 inhibition across different cancers, identifying markers of sensitivity and combinatorial therapeutic …
- Some results have been removed